← Feed

u/Weekly-Barracuda-494

2 theses · first seen Oct 20, 2026
WindowThesesResolvedWinsWin rateAvg returnMedian return
1d2200%-0.6%-0.6%
3d2200%-7.4%-7.4%
1w2200%-19.3%-19.3%
1m2200%-22.2%-22.2%
3m2200%-37.7%-37.7%
6m000———
1y000———

Past performance does not predict future results. Informational only, not investment advice.

Thesis history

$FBIOr/pennystocksGeneral Discussionbullish
u/Weekly-Barracuda-494 · 97d ago1 prior · 0% at 3mo

FBIO Positioned for Growth?

Fortress Biotech is a biotech holding company with a portfolio of revenue-generating and clinical-stage assets across multiple subsidiaries. With a market cap of $110M against projected Journey Medical sales of $86M alone, plus significant milestone and royalty payments from dotinurad, Zycubo, Unloxcyt, and other assets, the author views the stock as undervalued with potential for substantial upside.

At post $3.39Now $1.93-43.1% since postedas of Nov 2, 4:15 PM ET
1d-1.2%
3d-7.7%
1w-19.8%
1m-17.4%
3m-44.8%
6m—
1y—
original post →
$SPROr/pennystocksGeneral Discussionbullish
u/Weekly-Barracuda-494 · 111d ago1 prior · 0% at 3mo

Spero Therapeutics Changing focus

Spero Therapeutics monetized GSK royalty payments to fund a pivot toward developing an antibody asset from Innovent Biologics, with up to $326M in GSK milestone payments and enough capital to run Phase 2/3 trials without dilution, positioning the company for potential upside if the new asset succeeds clinically.

At post $1.70Now $1.07-37.1% since postedas of Oct 26, 4:15 PM ET
1d0.0%
3d-7.1%
1w-18.8%
1m-27.1%
3m-30.6%
6m—
1y—
original post →

End of results.